| Cat.No. | Name | Information |
|---|---|---|
| M21038 | MK2 Inhibitor III | MK2 Inhibitor III (MK2-IN-3) is an ATP-competitive MK2 (MAPKAP-K2) inhibitor with an IC50 value of 8.5 nM. |
| M8991 | Dilmapimod | Dilmapimod (also known as SB-681323 and GW-681323) is a p38 MAPK inhibitor that potentially suppresses inflammation in COPD. |
| M3751 | Losmapimod | Losmapimod (GW856553) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. |
| M2062 | SB 202190 | SB 202190 is a highly selective, potent and cell permeable inhibitor of p38 MAP kinase with IC50 values of 50 and 100 nM inhibiting p38α and p38β, respectively. |
| M1781 | Adezmapimod (SB203580) | Adezmapimod (SB203580) is a P38 MAPK inhibitor with an IC50 of 0.3-0.5 μM, which is 10 times less selective than SAPK3(106T) and SAPK4(106T), and inhibits PKB phosphorylation with an IC50 of 3-5 μM. |
| M1675 | BIRB796 | BIRB 796 (Doramapimod) is a protein kinase inhibitor of p38 MAPK with Kd of 100pM. |
| M1556 | Hesperetin | Hesperetin is a potent and broad-spectrum inhibitor against human UGT activity. |
| M54759 | HWY336 | HWY336 is a selective, non-ATP competitive dual MKK4 and MKK7 inhibitor with IC50 values of 6 µM on MKK4 and 10 µM on MKK7 in vitro. HWY336 inhibits the phosphorylation of MKK4/MKK7 inside the activation loop or hinders the substrate to access the kinase. |
| M42147 | Z16078526 | Z16078526 induces endogenous Ucp1 expression, promotes p38 MAPK phosphorylation and lipolysis in primary mouse brown adipocytes. |
| M30587 | Emprumapimod | Emprumapimod (PF-07265803) is a potent, orally active and selective inhibitor of p38α MAPK directly inhibits LPS-induced IL-6 production from RPMI-8226 cell (IC50=100 pM). Emprumapimod can be used for the research of dilated cardiomyopathy and acute inflammatory pain. |
| M29549 | Darizmetinib | Darizmetinib is an inhibitor of mitogen-activated protein kinase kinase (MAP2K). |
| M28610 | TAK1-IN-4 | TAK1-IN-4 (Compound 14) is a TAK1 inhibitor. |
| M25459 | Zunsemetinib | Zunsemetinib (CDD-450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. |
| M19388 | Chicanin | Chicanine is a lignan compound of Schisandra chinesis, inhibits LPS-induced phosphorylation of p38 MAPK, ERK 1/2 and IκB-α, with anti-inflammatory activity. |
| M18702 | Isobavachromene | Isobavachromene (4-Hydroxylonchocarpin) increases phosphorylation of p38 MAPK, JNK and ERK. 4-Hydroxylonchocarpin has diverse pharmacological activities, including antibacterial, antifungal, anticancer, antireverse transcriptase, antitubercular, antimalarial, anti-inflammatory and antioxidant activities. |
| M18061 | 3,4-Dihydroxybenzenepropanoic acid | 3,4-Dihydroxybenzenepropanoic acid is a microbial metabolite of flavonoids, reduces phosphorylation of MAPK p38, with antioxidant potential and anti-inflammatory activity. |
| M14180 | Talmapimod | Talmapimod (SCIO-469) is an orally active, selective, and ATP-competitive p38α inhibitor with an IC50 of 9 nM. |
| M14179 | SB 242235 | SB-242235 is a potent and selective p38 MAP kinase inhibitor, with an IC50 of 1.0 μM in primary human chondrocytes. |
| M14178 | p38 MAPK-IN-1 | p38 MAPK-IN-1 (Compound 4) is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM. p38 MAPK-IN-1 shows sustained levels, low clearance and good bioavailability. |
| M14177 | p38-α MAPK-IN-1 | p38-α MAPK-IN-1 is an inhibitor of MAPK14 (p38-α), with IC50 of 2300 nM in EFC displacement assay, and 5500 nM in HTRF assay. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
